Anti-Gpc3 Car-T Cells

Hepatocellular Carcinoma , Cholangiocarcinoma

Beijing Immunochina Medical Science & Technology Co., Ltd.Cell therapyEarly Phase 1Dormant

39/ 100

Provisional rating · Methodology v0.2

Rating breakdown

3 Active assets in the Hepatocellular Carcinoma , Cholangiocarcinoma cohort.

Asset / Sponsor	Phase	Rating
IMMUNOGLOBULIN G1, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYPE VEGFR-2 EXTRACELLULAR DOMAIN) (HUMAN MONOCLONAL IMC-1121B .GAMMA.-CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL IMC-1121B .KAPPA.-CHAIN, DIMER M.D. Anderson Cancer Center	Phase 2	B
azd6244 National Cancer Institute (NCI)	Phase 2	B
Floxuridine OHSU Knight Cancer Institute	Phase 2	CCC
DEXAMETHASONE OHSU Knight Cancer Institute	Phase 2	CCC
Eloxatin OHSU Knight Cancer Institute	Phase 2	CCC

View all 9 →

Order a full diligence report on this asset.

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.